Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021

Upgrades

For Cabot Oil & Gas Corp COG, Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the second quarter, Cabot Oil & Gas had an EPS of $0.26, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $23.10 and a 52-week-low of $14.28. At the end of the last trading period, Cabot Oil & Gas closed at $22.55.

For Pearson PLC PSO, Kepler Cheuvreux upgraded the previous rating of Reduce to Hold. At the moment, the stock has a 52-week-high of $12.38 and a 52-week-low of $6.38. Pearson closed at $9.63 at the end of the last trading period.

According to UBS, the prior rating for Kraton Corp KRA was changed from Sell to Neutral. For the second quarter, Kraton had an EPS of $0.32, compared to year-ago quarter EPS of $0.30. The current stock performance of Kraton shows a 52-week-high of $46.25 and a 52-week-low of $16.50. Moreover, at the end of the last trading period, the closing price was at $45.45.

For Compass Minerals International Inc CMP, Monness, Crespi, Hardt upgraded the previous rating of Neutral to Buy. Compass Minerals Intl earned $0.49 in the second quarter, compared to $0.04 in the year-ago quarter. The current stock performance of Compass Minerals Intl shows a 52-week-high of $72.00 and a 52-week-low of $54.24. Moreover, at the end of the last trading period, the closing price was at $64.02.

For Jabil Inc JBL, Stifel upgraded the previous rating of Hold to Buy. In the fourth quarter, Jabil showed an EPS of $1.44, compared to $0.98 from the year-ago quarter. The stock has a 52-week-high of $63.78 and a 52-week-low of $31.41. At the end of the last trading period, Jabil closed at $57.23.

According to Redburn Partners, the prior rating for Barclays PLC BCS was changed from Neutral to Buy. For the second quarter, Barclays had an EPS of $0.17, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $10.78 and a 52-week-low of $4.92. At the end of the last trading period, Barclays closed at $10.25.

UBS upgraded the previous rating for FactSet Research Systems Inc FDS from Sell to Neutral. In the fourth quarter, FactSet Research Systems showed an EPS of $2.88, compared to $2.88 from the year-ago quarter. At the moment, the stock has a 52-week-high of $399.00 and a 52-week-low of $294.21. FactSet Research Systems closed at $394.51 at the end of the last trading period.

According to Truist Securities, the prior rating for Asbury Automotive Group Inc ABG was changed from Hold to Buy. For the second quarter, Asbury Automotive Group had an EPS of $7.78, compared to year-ago quarter EPS of $2.52. At the moment, the stock has a 52-week-high of $216.88 and a 52-week-low of $93.79. Asbury Automotive Group closed at $203.24 at the end of the last trading period.

According to Wells Fargo, the prior rating for PS Business Parks Inc PSB was changed from Underweight to Equal-Weight. For the second quarter, PS Business Parks had an EPS of $1.75, compared to year-ago quarter EPS of $1.59. At the moment, the stock has a 52-week-high of $165.85 and a 52-week-low of $109.26. PS Business Parks closed at $158.50 at the end of the last trading period.

Rosenblatt upgraded the previous rating for Fox Corp FOXA from Neutral to Buy. Fox earned $0.65 in the fourth quarter, compared to $0.62 in the year-ago quarter. The stock has a 52-week-high of $44.80 and a 52-week-low of $24.93. At the end of the last trading period, Fox closed at $40.25.

For Snowflake Inc SNOW, BTIG upgraded the previous rating of Neutral to Buy. In the second quarter, Snowflake earned $0.04. The stock has a 52-week-high of $429.00 and a 52-week-low of $184.71. At the end of the last trading period, Snowflake closed at $293.80.

According to Jefferies, the prior rating for Perrigo Co PLC PRGO was changed from Hold to Buy. Perrigo earned $0.50 in the second quarter, compared to $1.03 in the year-ago quarter. The stock has a 52-week-high of $49.91 and a 52-week-low of $38.20. At the end of the last trading period, Perrigo closed at $43.50.

According to Raymond James, the prior rating for Black Knight Inc BKI was changed from Market Perform to Outperform. For the second quarter, Black Knight had an EPS of $0.57, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $97.19 and a 52-week-low of $68.60. At the end of the last trading period, Black Knight closed at $71.22.

For Public Service Enterprise Group Inc PEG, Vertical Research upgraded the previous rating of Hold to Buy. For the second quarter, Public Service Enterprise had an EPS of $0.70, compared to year-ago quarter EPS of $0.79. The current stock performance of Public Service Enterprise shows a 52-week-high of $65.33 and a 52-week-low of $53.77. Moreover, at the end of the last trading period, the closing price was at $61.26.

According to JP Morgan, the prior rating for Amicus Therapeutics Inc FOLD was changed from Neutral to Overweight. For the second quarter, Amicus Therapeutics had an EPS of $0.19, compared to year-ago quarter EPS of $0.20. At the moment, the stock has a 52-week-high of $25.39 and a 52-week-low of $8.60. Amicus Therapeutics closed at $9.66 at the end of the last trading period.

For Aroundtown SA AANNF, Goldman Sachs upgraded the previous rating of Neutral to Buy. The stock has a 52-week-high of $8.53 and a 52-week-low of $4.97. At the end of the last trading period, Aroundtown closed at $6.99.

According to BMO Capital, the prior rating for Pactiv Evergreen Inc PTVE was changed from Market Perform to Outperform. Pactiv Evergreen earned $0.04 in the second quarter. The stock has a 52-week-high of $19.61 and a 52-week-low of $10.57. At the end of the last trading period, Pactiv Evergreen closed at $11.89.

See all analyst ratings upgrades.

Downgrades

For Scout24 AG SCOTF, JP Morgan downgraded the previous rating of Overweight to Neutral. The current stock performance of Scout24 shows a 52-week-high of $84.43 and a 52-week-low of $77.58. Moreover, at the end of the last trading period, the closing price was at $83.12.

According to Piper Sandler, the prior rating for Acceleron Pharma Inc XLRN was changed from Overweight to Neutral. Acceleron Pharma earned $1.05 in the second quarter, compared to $0.34 in the year-ago quarter. The stock has a 52-week-high of $189.99 and a 52-week-low of $99.98. At the end of the last trading period, Acceleron Pharma closed at $175.36.

According to Truist Securities, the prior rating for Healthcare Trust of America Inc HTA was changed from Buy to Hold. For the second quarter, Healthcare Trust had an EPS of $0.44, compared to year-ago quarter EPS of $0.42. At the moment, the stock has a 52-week-high of $31.31 and a 52-week-low of $23.39. Healthcare Trust closed at $30.48 at the end of the last trading period.

B of A Securities downgraded the previous rating for Kohl's Corp KSS from Buy to Underperform. In the second quarter, Kohl's showed an EPS of $2.48, compared to $0.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.80 and a 52-week-low of $18.28. Kohl's closed at $53.66 at the end of the last trading period.

Stephens & Co. downgraded the previous rating for Ameris Bancorp ABCB from Overweight to Equal-Weight. For the second quarter, Ameris had an EPS of $1.25, compared to year-ago quarter EPS of $0.61. The stock has a 52-week-high of $59.85 and a 52-week-low of $22.07. At the end of the last trading period, Ameris closed at $53.29.

Atlantic Equities downgraded the previous rating for Starbucks Corp SBUX from Overweight to Neutral. Starbucks earned $1.01 in the third quarter, compared to $0.46 in the year-ago quarter. The current stock performance of Starbucks shows a 52-week-high of $126.32 and a 52-week-low of $84.62. Moreover, at the end of the last trading period, the closing price was at $112.17.

JP Morgan downgraded the previous rating for G1 Therapeutics Inc GTHX from Overweight to Neutral. In the second quarter, G1 Therapeutics showed an EPS of $0.94, compared to $0.83 from the year-ago quarter. The stock has a 52-week-high of $37.07 and a 52-week-low of $10.81. At the end of the last trading period, G1 Therapeutics closed at $14.89.

See all analyst ratings downgrades.

Initiations

Craig-Hallum initiated coverage on Zuora Inc ZUO with a Buy rating. The price target for Zuora is set to $24.00. For the second quarter, Zuora had an EPS of $0.04, compared to year-ago quarter EPS of $0.00. The current stock performance of Zuora shows a 52-week-high of $18.65 and a 52-week-low of $9.27. Moreover, at the end of the last trading period, the closing price was at $16.64.

JP Morgan initiated coverage on Lithium Americas Corp LAC with an Overweight rating. The price target for Lithium Americas is set to $28.00. Lithium Americas earned $0.16 in the second quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $28.75 and a 52-week-low of $8.95. At the end of the last trading period, Lithium Americas closed at $20.51.

Morgan Stanley initiated coverage on Janus International Group Inc JBI with a Equal-Weight rating. The price target for Janus Intl Gr is set to $14.00. In the second quarter, Janus Intl Gr showed an EPS of $0.02, compared to $0.17 from the year-ago quarter. The stock has a 52-week-high of $15.94 and a 52-week-low of $12.06. At the end of the last trading period, Janus Intl Gr closed at $12.68.

Imperial Capital initiated coverage on Snap One Holdings Corp SNPO with an Outperform rating. The price target for Snap One Holdings is set to $25.00. Snap One Holdings earned $0.23 in the second quarter. The stock has a 52-week-high of Missing 52-Week High and a 52-week-low of Missing 52-Week Low . At the end of the last trading period, Snap One Holdings closed at $15.76.

With an Outperform rating, Wolfe Research initiated coverage on Malibu Boats Inc MBUU. The price target seems to have been set at $81.00 for Malibu Boats. For the fourth quarter, Malibu Boats had an EPS of $1.84, compared to year-ago quarter EPS of $0.40. At the moment, the stock has a 52-week-high of $93.00 and a 52-week-low of $47.56. Malibu Boats closed at $70.46 at the end of the last trading period.

Wolfe Research initiated coverage on OneWater Marine Inc ONEW with an Outperform rating. The price target for OneWater Marine is set to $45.00. OneWater Marine earned $3.04 in the third quarter, compared to $2.36 in the year-ago quarter. The current stock performance of OneWater Marine shows a 52-week-high of $56.77 and a 52-week-low of $18.01. Moreover, at the end of the last trading period, the closing price was at $41.00.

Wolfe Research initiated coverage on The Chefs' Warehouse Inc CHEF with an Outperform rating. The price target for The Chefs' Warehouse is set to $38.00. In the second quarter, The Chefs' Warehouse showed an EPS of $0.04, compared to $0.52 from the year-ago quarter. The current stock performance of The Chefs' Warehouse shows a 52-week-high of $35.56 and a 52-week-low of $12.35. Moreover, at the end of the last trading period, the closing price was at $32.10.

Stifel initiated coverage on Rocket Lab USA Inc RKLB with a Buy rating. The price target for Rocket Lab USA is set to $22.00. At the moment, the stock has a 52-week-high of Missing 52-Week High and a 52-week-low of Missing 52-Week Low . Rocket Lab USA closed at $14.66 at the end of the last trading period.

With an Outperform rating, Cowen & Co. initiated coverage on Sema4 Holdings Corp SMFR. The price target seems to have been set at $13.00 for Sema4 Holdings. Interestingly, in the second quarter, Sema4 Holdings's EPS was $0.00. At the moment, the stock has a 52-week-high of Missing 52-Week High and a 52-week-low of Missing 52-Week Low . Sema4 Holdings closed at $7.44 at the end of the last trading period.

Seaport Global initiated coverage on Navient Corp NAVI with a Neutral rating. Navient earned $0.98 in the second quarter, compared to $0.91 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.80 and a 52-week-low of $7.89. Navient closed at $19.24 at the end of the last trading period.

Wells Fargo initiated coverage on Itron Inc ITRI with a Equal-Weight rating. The price target for Itron is set to $75.00. In the second quarter, Itron showed an EPS of $0.28, compared to $0.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $122.31 and a 52-week-low of $58.44. Itron closed at $79.15 at the end of the last trading period.

With a Neutral rating, Daiwa Capital initiated coverage on Zscaler Inc ZS. The price target seems to have been set at $266.00 for Zscaler. Zscaler earned $0.14 in the fourth quarter, compared to $0.05 in the year-ago quarter. The current stock performance of Zscaler shows a 52-week-high of $293.44 and a 52-week-low of $120.34. Moreover, at the end of the last trading period, the closing price was at $258.88.

With a Neutral rating, B. Riley Securities initiated coverage on Kymera Therapeutics Inc KYMR. The price target seems to have been set at $67.00 for Kymera Therapeutics. Kymera Therapeutics earned $0.55 in the second quarter. The current stock performance of Kymera Therapeutics shows a 52-week-high of $91.92 and a 52-week-low of $27.65. Moreover, at the end of the last trading period, the closing price was at $58.45.

B. Riley Securities initiated coverage on Bicycle Therapeutics PLC BCYC with a Buy rating. The price target for Bicycle Therapeutics is set to $56.00. In the second quarter, Bicycle Therapeutics showed an EPS of $0.74, compared to $0.67 from the year-ago quarter. The stock has a 52-week-high of $45.21 and a 52-week-low of $17.68. At the end of the last trading period, Bicycle Therapeutics closed at $39.07.

With an Overweight rating, Barclays initiated coverage on R1 RCM Inc RCM. The price target seems to have been set at $28.00 for R1 RCM. In the second quarter, R1 RCM showed an EPS of $0.06, compared to $0.03 from the year-ago quarter. The stock has a 52-week-high of $31.28 and a 52-week-low of $16.62. At the end of the last trading period, R1 RCM closed at $21.54.

With a Buy rating, Berenberg initiated coverage on Progyny Inc PGNY. The price target seems to have been set at $81.00 for Progyny. For the second quarter, Progyny had an EPS of $0.19, compared to year-ago quarter EPS of $0.02. The current stock performance of Progyny shows a 52-week-high of $66.61 and a 52-week-low of $23.56. Moreover, at the end of the last trading period, the closing price was at $55.35.

Berenberg initiated coverage on Accolade Inc ACCD with a Buy rating. The price target for Accolade is set to $61.00. For the first quarter, Accolade had an EPS of $0.66, compared to year-ago quarter EPS of $1.86. The stock has a 52-week-high of $65.25 and a 52-week-low of $32.87. At the end of the last trading period, Accolade closed at $41.36.

HC Wainwright & Co. initiated coverage on Ultragenyx Pharmaceutical Inc RARE with a Buy rating. The price target for Ultragenyx Pharmaceutical is set to $106.00. For the second quarter, Ultragenyx Pharmaceutical had an EPS of $1.81, compared to year-ago quarter EPS of $1.12. The current stock performance of Ultragenyx Pharmaceutical shows a 52-week-high of $179.65 and a 52-week-low of $76.78. Moreover, at the end of the last trading period, the closing price was at $86.12.

With an Outperform rating, Telsey Advisory Group initiated coverage on Zevia PBC ZVIA. The price target seems to have been set at $15.00 for Zevia. Zevia earned $0.30 in the second quarter. The current stock performance of Zevia shows a 52-week-high of Missing 52-Week High and a 52-week-low of Missing 52-Week Low . Moreover, at the end of the last trading period, the closing price was at $11.01.

JP Morgan initiated coverage on Karuna Therapeutics Inc KRTX with an Overweight rating. The price target for Karuna Therapeutics is set to $162.00. For the second quarter, Karuna Therapeutics had an EPS of $1.17, compared to year-ago quarter EPS of $0.65. The current stock performance of Karuna Therapeutics shows a 52-week-high of $146.97 and a 52-week-low of $74.06. Moreover, at the end of the last trading period, the closing price was at $118.85.

With a Buy rating, Stifel initiated coverage on Kymera Therapeutics Inc KYMR. The price target seems to have been set at $80.00 for Kymera Therapeutics. In the second quarter, Kymera Therapeutics earned $0.55. The stock has a 52-week-high of $91.92 and a 52-week-low of $27.65. At the end of the last trading period, Kymera Therapeutics closed at $58.45.

Stifel initiated coverage on Arvinas Inc ARVN with a Buy rating. The price target for Arvinas is set to $115.00. For the second quarter, Arvinas had an EPS of $1.03, compared to year-ago quarter EPS of $0.65. The stock has a 52-week-high of $108.47 and a 52-week-low of $19.68. At the end of the last trading period, Arvinas closed at $82.57.

With a Hold rating, Stifel initiated coverage on Turning Point Therapeutics Inc TPTX. The price target seems to have been set at $75.00 for Turning Point. For the second quarter, Turning Point had an EPS of $1.14, compared to year-ago quarter EPS of $0.82. The current stock performance of Turning Point shows a 52-week-high of $141.30 and a 52-week-low of $59.73. Moreover, at the end of the last trading period, the closing price was at $68.07.

With a Hold rating, Stifel initiated coverage on Black Diamond Therapeutics Inc BDTX. The price target seems to have been set at $10.00 for Black Diamond Therapeutic. Black Diamond Therapeutic earned $0.95 in the second quarter, compared to $0.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $37.76 and a 52-week-low of $8.75. Black Diamond Therapeutic closed at $9.06 at the end of the last trading period.

Stifel initiated coverage on Zentalis Pharmaceuticals Inc ZNTL with a Buy rating. The price target for Zentalis Pharmaceuticals is set to $84.00. Zentalis Pharmaceuticals earned $1.34 in the second quarter, compared to $0.78 in the year-ago quarter. The current stock performance of Zentalis Pharmaceuticals shows a 52-week-high of $74.99 and a 52-week-low of $28.99. Moreover, at the end of the last trading period, the closing price was at $61.48.

With a Buy rating, Stifel initiated coverage on Affimed NV AFMD. The price target seems to have been set at $12.00 for Affimed. Affimed earned $0.19 in the second quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $11.74 and a 52-week-low of $3.08. Affimed closed at $5.85 at the end of the last trading period.

With a Hold rating, Stifel initiated coverage on C4 Therapeutics Inc CCCC. The price target seems to have been set at $45.00 for C4 Therapeutics. Interestingly, in the second quarter, C4 Therapeutics's EPS was $0.51. The stock has a 52-week-high of $51.21 and a 52-week-low of $22.40. At the end of the last trading period, C4 Therapeutics closed at $47.97.

With a Buy rating, Stifel initiated coverage on ALX Oncology Holdings Inc ALXO. The price target seems to have been set at $106.00 for ALX Oncology Holdings. ALX Oncology Holdings earned $0.35 in the second quarter, compared to $0.22 in the year-ago quarter. At the moment, the stock has a 52-week-high of $117.45 and a 52-week-low of $32.51. ALX Oncology Holdings closed at $73.36 at the end of the last trading period.

See all analyst ratings initiations.